The SARM compounds were in-licensed by Radius with the intention to develop new compounds for treatment of osteoporosis. Karo Bio has now reacquired all rights to the SARM compounds and to related data generated by Radius.
Per Olof Wallstrom, president of Karo Bio, said: “There are several therapeutic opportunities for compounds targeting the androgen receptor, and the retained rights and data to the SARMs add value to our technology base.”